Zevra Therapeutics Shares Plunge After EU Rejects Arimoclomol for Rare Disease
Company plans to request re-examination.
/ 2 items
Company plans to request re-examination.
BTIG starts coverage on ZVRA with Buy rating and $23 target after Zevra sells SDX portfolio for $50 million and becomes debt-free.